The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

I.b

Pneumonitis (interstitial lung disease/ILD)

Publications

Kawata T, Higashimori M, Itoh Y, Tomkinson H, Johnson MG, Tang W, Nyberg F, Jiang H, Tanigawara Y

Gefitinib exposure and occurrence of interstitial lung disease in Japanese patients with non-small-cell lung cancer.

Cancer chemotherapy and pharmacology. 2019;83(5):849-858

Akamatsu H, Inoue A, Mitsudomi T, Kobayashi K, Nakagawa K, Mori K, Nukiwa T, Nakanishi Y, Yamamoto N

Interstitial lung disease associated with gefitinib in Japanese patients with EGFR-mutated non-small-cell lung cancer: combined analysis of two Phase III trials (NEJ 002 and WJTOG 3405).

Japanese journal of clinical oncology. 2013;43(6):664-8

Zhang Y, Yang H, Zhao M, He J

Successful treatment of gefitinib-induced acute interstitial pneumonitis with corticosteroid and non-invasive BIPAP-ventilation.

Journal of thoracic disease. 2012;4(3):316-9

Nyberg F, Barratt BJ, Mushiroda T, Takahashi A, Jawaid A, Hada S, Umemura T, Fukuoka M, Nakata K, Ohe Y, Kato H, Kudoh S, March R, Nakamura Y, Kamatani N

Interstitial lung disease in gefitinib-treated Japanese patients with non-small-cell lung cancer: genome-wide analysis of genetic data.

Pharmacogenomics. 2011;12(7):965-75

Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Ogura T, Ando M, Miyazawa H, Tanaka T, Saijo Y, Hagiwara K, Morita S, Nukiwa T, North-East

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.

The New England journal of medicine. 2010;362(25):2380-8

Nakagawa M, Nishimura T, Teramukai S, Tada H, Tanaka F, Yanagihara K, Furuse K, Wada H, Fukushima M

Interstitial lung disease in gefitinib-treated Japanese patients with non-small cell lung cancer - a retrospective analysis: JMTO LC03-02.

BMC research notes. 2009;2:157

Kudoh S, Kato H, Nishiwaki Y, Fukuoka M, Nakata K, Ichinose Y, Tsuboi M, Yokota S, Nakagawa K, Suga M, Japan Thoracic Radiology Group, Jiang H, Itoh Y, Armour A, Watkins C, Higenbottam T, Nyberg F

Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study.

American journal of respiratory and critical care medicine. 2008;177(12):1348-57

Endo M, Johkoh T, Kimura K, Yamamoto N

Imaging of gefitinib-related interstitial lung disease: multi-institutional analysis by the West Japan Thoracic Oncology Group.

Lung cancer (Amsterdam, Netherlands). 2006;52(2):135-40

Takano T, Ohe Y, Kusumoto M, Tateishi U, Yamamoto S, Nokihara H, Yamamoto N, Sekine I, Kunitoh H, Tamura T, Kodama T, Saijo N

Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib.

Lung cancer (Amsterdam, Netherlands). 2004;45(1):93-104